ClinicalTrials.gg
CompletedNCT01701804Updated Nov 7, 2018

The Effectiveness of Non-surgical Integrative Package on Failed Back Surgery Syndrome

An observational study in Failed Back Surgery Syndrome, sponsored by Jaseng Hospital of Korean Medicine. Completed at 2 sites in Korea, Republic of. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2018-11-07.

Sponsored by Jaseng Hospital of Korean Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 69 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the effect of a non-surgical integrative package consisting of Chuna herbal medicine, Chuna manual therapy, bee-venom pharmacoacupuncture, acupuncture on failed back surgery syndrome through means of a prospective case series.

Read the detailed description

The purpose of this study is to investigate the effect of a non-surgical integrative package on failed back surgery syndrome through means of a prospective case series.

After initial screening, treatment will be administered one session a week for 16 weeks. Patients will be followed up at 4 and 8 weeks after conclusion of treatment.

The integrative package used in this study consists of 120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) and dried extracts in pill form(Cibotium barometz, Atractylodes japonica) taken twice a day 30 minutes after meals, Chuna manual therapy, intermuscular injections of bee-venom pharmacoacupuncture(Select 6 acupoints, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session), acupuncture and allow for NSAID intake during the investigational period. The subject is allowed a maximum of 3 pills/day, taken at a minimum of 8 hrs apart. The number of pills taken will be measured at 4 wks after conclusion of treatment.

02

Conditions studied

  • Failed Back Surgery Syndrome

Keywords

  • Failed Back Surgery Syndrome
03

In context

Failed Back Surgery Syndrome

104 studies on the registry are indexed under Failed Back Surgery Syndrome; 15 are open to participants now.

This study's enrollment of 120 is above the median of 86 across 26 observational studies indexed under Failed Back Surgery Syndrome.

Browse Failed Back Surgery Syndrome studies →

Lead sponsor

Jaseng Hospital of Korean Medicine is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive patient sampling within Failed Back Surgery Syndrome clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suffering from low back pain and/or leg pain that does not improve or the return of the symptoms within 1 year of spinal surgery
  • Low back pain and/or leg pain with duration at least 3 weeks at baseline
  • Low back pain and/or leg pain at least 60mm on VAS scale
  • Age between 18 and 60
  • Given consent to lumbar MRI
  • Voluntary participation with written consent given to study consent form
  • Given consent to not receive other treatment concerning pain due to spinal disorders during study participation period

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of serious disease(s) which are possible causes of back pain such as , vertebral fracture, spinal infection, inflammatory spondylitis, cauda equina compression, etc.
  • Prior diagnosis of other chronic disease(s) which could affect effectiveness or interpretation of treatment results such as cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, Alzheimer's disease, epilepsy, etc.
  • Progressive neurologic deficit(s) or concurrent severe neurological symptoms
  • Unsuitable for or at risk of complications from acupuncture treatment such as patients with clotting disorders, severe diabetes with risk of infection, serious cardiovascular disease, or undergoing anticoagulant treatment, etc.
  • Under prescription of , immuno-suppressant drugs, psychiatric medicine, or other medication considered unsuitable for subjects by the researcher
  • Experience of gastroenteric complications after taking NSAIDs or currently undergoing treatment for digestive disorders
  • During pregnancy or suspected pregnancy
  • Subjects considered unsuitable for clinical trial by the researcher
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (actual)

Groups and cohorts

  • integrative treatment

    Drug: Chuna herbal medicine · Procedure: Chuna manual therapy · Procedure: Acupuncture · Procedure: Bee-venom pharmacoacupuncture

Interventions

  • DrugChuna herbal medicine

    120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks

  • ProcedureChuna manual therapy

    A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.

    Also known as: Chuna manipulation

  • ProcedureAcupuncture

    Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10\~20 acupoints once a week for 16 weeks.

  • ProcedureBee-venom pharmacoacupuncture

    Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.

    Also known as: BV, Bee-venom therapy

06

What researchers measure

Primary outcomes

  1. VAS of low back pain

    Time frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week, 14th week, 16th week, 24th week

  2. VAS of radiating leg pain

    Time frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week, 14th week, 16th week, 24th week

Secondary outcomes

  1. ODI (Oswestry Disability Index)

    Time frame: Baseline, 4th week, 8th week, 12th week, 16th week, 24th week

  2. SF-36 (Quality of Life)

    Time frame: Baseline, 4th week, 8th week, 12th week, 16th week, 24th week

  3. General assessment(patient/doctor)

    General assessment of improvement by doctor and patient

    Time frame: 16th week, 24th week

07

Study locations

2 sites
  • Jaseng Hospital of Oriental Medicine
    Bucheon, Gyeonggi Province 420-814, Korea, Republic of
  • Jaseng Hospital of Oriental Medicine
    Seoul, 135-896, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2011 to primary completion in Sep 2014, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2011
First posted
Oct 5, 2012
StartActual
Sep 2011
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Last update
Nov 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01701804
Lead sponsor
Jaseng Hospital of Korean Medicine
Responsible party
Sponsor
First posted
Oct 5, 2012
Start date
Sep 2011
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Nov 7, 2018

Study contacts

Joonshik Shin, OMD, Ph.D
principal investigator · Jaseng Hospital of Korean Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion